Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Breast Cancer

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Spinraza managed access deal in England breaks deadlock for Biogen

Patient groups remain wary, call for changes to NICE

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

- PMLiVE

Deadly measles outbreaks on the rise, social media called to account

Firms called on to fight anti-vax fake news

The Orkambi row explained

Q&A and timeline

- PMLiVE

The Orkambi blame game

Grilling by MPs sheds some light on long-running row over CF drug

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

- PMLiVE

Leader named for NHS digital transformation unit, but scepticism persists

NHS managers question logic of another authority

- PMLiVE

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links